



## Kura Oncology to Report Second Quarter 2022 Financial Results

July 27, 2022

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

To participate in the teleconference, domestic callers should dial 1-888-882-4478 and international callers should dial 1-323-794-2590 and reference conference ID: 8696904. A live webcast presentation can also be accessed using this weblink: [https://viaavid.webcasts.com/starthere.jsp?ei=1561186&tp\\_key=10754ad253](https://viaavid.webcasts.com/starthere.jsp?ei=1561186&tp_key=10754ad253). A replay of the webcast will be available online from the investor relations section of the company website at [www.kuraoncology.com](http://www.kuraoncology.com).

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3K $\alpha$  inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3K $\alpha$  pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated NSCLC. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company's next-generation FTI, through IND-enabling studies. For additional information, please visit Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### Contacts

Company:

Pete De Spain

Senior Vice President, Investor Relations &  
Corporate Communications

(858) 500-8803

[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

Investors:

Robert H. Uhl

Managing Director

ICR Westwicke

(858) 356-5932

[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

Media:

Jason Spark

Managing Director

Canale Communications

(619) 849-6005

[jason@canalecomm.com](mailto:jason@canalecomm.com)



Source: Kura Oncology, Inc.